Tokio Marine HCC and Susan G. Komen® Team Up Once Again with Golf Champion Nelly Korda to Help End Breast Cancer
WAKEFIELD, Mass., May 25, 2025 (GLOBE NEWSWIRE) — With the 80th edition of the biggest women's U.S. golf tournament starting on May 29, Susan G. Komen®, the world's leading breast cancer organization, is once again proud to partner with Tokio Marine HCC (TMHCC), one of the world's leading specialty insurers, and Nelly Korda, the number one-ranked women's golfer in the world, to support efforts to end breast cancer and bring vital resources to those affected by the disease.
This year alone, it is estimated that 316,9501 women in the U.S. will be diagnosed with invasive breast cancer for the first time. Tragically, it is also expected that 42,1701 will succumb to the disease, which disregards age, gender, socio-economic status or location.
Latest research indicates that by making modern treatments accessible to everyone, roughly one-third of U.S. breast cancer deaths could be prevented. In support of this cause, TMHCC will once again support Susan G. Komen's Swing for a Cure campaign by donating $5,000 for every birdie and $10,000 for every eagle that Korda scores during the tournament, with a guaranteed minimum donation of $50,000.
Extending its support for this year's campaign, TMHCC will also donate $25,000 should Korda shoot a hole in one during the tournament, $100,000 should she win by three strokes, $500,000 should she win by four, and $1 million should she win by five or more.
'We are so excited to be spearheading this fantastic partnership again this year, extending our support for such a worthy cause. At TMHCC, a sense of responsibility and duty to our community has always been a key driving force behind our work. It is with great pride that we are able to collaborate with Susan G. Komen and Nelly Korda to raise awareness of breast cancer, fund research for critical treatment, and one day eradicate it as a life-threatening disease,' said Tokio Marine HCC's CEO Susan Rivera.
'At Susan G. Komen, we believe in the power of women supporting women — lifting each other up through challenges and triumphs alike,' said Paula Schneider, President & CEO of Susan G. Komen. 'That's why we're once again so proud to stand beside Nelly, a true champion on and off the course, helping to shine a light on the critical needs of families facing breast cancer. In fact, last year alone, thanks to the generosity of supporters like TMHCC, Komen was able to deliver nearly 43,000 direct patient services and $7.5 million in financial assistance to thousands of individuals navigating breast cancer. We're deeply grateful to TMHCC for their ongoing partnership, and we'll be cheering Nelly on every step of the way!'
To learn more, follow the campaign and make donations, please visit www.swingforcure.com.
As part of the Tokio Marine Group family, TMHCC is driven by the philosophy of 'Inspiring Confidence. Accelerating Progress.' As a socially responsible organization that looks beyond profit, TMHCC helps build more resilient economies, industries and societies in a rapidly changing world. This has been TMHCC's mission since its founding and will remain its guiding purpose.
About Tokio Marine HCC
Tokio Marine HCC is a member of the Tokio Marine Group, a premier global company founded in 1879 with a market capitalization of $74 billion as of March 31, 2025. Headquartered in Houston, Texas, Tokio Marine HCC is a leading specialty insurance group with offices in the United States, Mexico, the United Kingdom and Continental Europe. Tokio Marine HCC's major domestic insurance companies have financial strength ratings of 'A+' (Strong) from S&P Global Ratings, 'A++' (Superior) from AM Best, and 'AA-' (Very Strong) from Fitch Ratings; its major international insurance companies have financial strength ratings of 'A+' (Strong) from S&P Global Ratings. Tokio Marine HCC is the marketing name used to describe the affiliated companies under the common ownership of HCC Insurance Holdings, Inc., a Delaware-incorporated insurance holding company. For more information about Tokio Marine HCC, please visit www.tokiomarinehcc.com. Media Contact: Sean Curtin President & CUO – Contingency & SHEL Tokio Marine HCC – Specialty Group [email protected] 781.258.9232
About Susan G. Komen®
Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
_______________
1 https://www.komen.org/breast-cancer/facts-statistics/breast-cancer-statistics/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
$13.16 Bn Human Growth Hormone (HGH) Market Trends and Forecasts, 2020-2024 & 2025-2030: Strategic R&D Initiatives, Regulatory Approvals, and Collaborations Shaping the Landscape
The Human Growth Hormone market offers significant opportunities driven by the rise in growth hormone deficiencies and aging populations seeking HGH therapy. The demand is boosted by potential anti-aging and wellness benefits, with biosimilars presenting a cost-effective alternative. Key challenges include high costs and ethical issues. Human Growth Hormone (HGH) Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Human Growth Hormone (HGH) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Human Growth Hormone (HGH) Market was valued at USD 6.21 Billion in 2024, and is expected to reach USD 13.16 Billion by 2030, rising at a CAGR of 13.29% This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin - a crucial hormone produced by the pituitary gland - to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement Market Drivers Increasing Prevalence of Growth Hormone Deficiency (GHD)The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions Market Challenges High CostCost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH Market Trends BiosimilarsThe growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.21 Billion Forecasted Market Value (USD) by 2030 $13.16 Billion Compound Annual Growth Rate 13.2% Regions Covered Global Report Scope: Key Market Players Novo Nordisk A/S Eli Lilly and Company Pfizer, Inc. Sandoz International GmbH (Novartis AG) Genentech, Inc. (Roche) Merck KGaA Ferring Pharmaceuticals Ipsen Pharma Teva Pharmaceutical Industries, Ltd. Human Growth Hormone (HGH) Market, By Product: Long Acting Others Human Growth Hormone (HGH) Market, By Application: Growth Hormone (GH) Deficiency Turner Syndrome Idiopathic Short Stature Prader-Willi Syndrome Small for Gestational Age Other Human Growth Hormone (HGH) Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy Human Growth Hormone (HGH) Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Growth Hormone (HGH) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Revolutionizing Drug Discovery: DNA-Encoded Libraries Market Set to Double Growth by 2030 with a 13.51% CAGR
The DNA-encoded Library market is driven by rising demand for efficient drug discovery methods, as DEL technology enables rapid, cost-effective screening of compounds. Key opportunities include integration with AI and ML for enhanced analysis, and increased R&D in personalized medicine, fueling DEL adoption across therapeutic areas. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "DNA-encoded Library Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The DNA-encoded Library Market was valued at USD 0.76 billion in 2024, and is expected to reach USD 1.63 billion by 2030, rising at a CAGR of 13.51%. DEL technology is revolutionizing early-stage drug discovery by enabling simultaneous screening of billions of compounds, which enhances efficiency and accelerates hit identification. As pharmaceutical and biotech companies seek scalable, cost-effective platforms for bioactive molecule discovery, DELs are gaining traction due to their high-throughput capabilities and chemical diversity. Increased R&D investment, growing interest in personalized medicine, and the demand for faster therapeutic development continue to drive adoption. Integration of artificial intelligence and machine learning into DEL workflows further enhances compound analysis, lead selection, and predictive modeling. With technological innovations in encoding chemistries and compound scaffolds, and the emergence of hybrid screening strategies, the DEL market is poised for continued robust growth. Key Market Drivers Rising Demand for Efficient Drug Discovery Methods The surge in demand for efficient drug discovery methods is a major factor driving the growth of the DEL market. Traditional drug discovery involves extensive time and financial investment, often with low success rates. DELs address this issue by enabling the rapid screening of billions of small molecules tagged with unique DNA barcodes, allowing researchers to identify promising interactions with target proteins more effectively. This method significantly reduces the time and cost associated with early-stage drug development. As pharmaceutical companies aim to speed up the development of targeted therapies for complex conditions such as cancer and neurological disorders, the scalability and precision of DEL technology offer a compelling advantage. The ability to explore vast chemical spaces and develop tailored treatments aligns with the industry's shift toward precision medicine, reinforcing DEL's role as a vital tool in modern drug discovery. Key Market Challenges Complexity of Library Design and Synthesis The intricate process of designing and synthesizing DNA-encoded libraries presents a key challenge to market growth. Creating diverse libraries requires specialized expertise in conjugating small molecules with DNA tags, with multiple synthesis steps that must be precisely executed. Maintaining the fidelity and reproducibility of libraries across large datasets is a technical hurdle, as errors in encoding can lead to inaccurate screening outcomes. Additionally, balancing chemical diversity with biological compatibility limits the scope of compound design. Some complex molecules or desired modifications may be difficult to synthesize or require extensive refinement, increasing time and costs. These complexities affect consistency and scalability, especially during transition from discovery to lead optimization. Key Market Trends Increasing Adoption of High-Throughput Screening Technologies High-throughput screening (HTS) technologies are becoming increasingly integrated with DEL platforms, enabling rapid evaluation of millions to billions of compounds. This combination boosts drug discovery efficiency by reducing time and cost while increasing hit identification accuracy. Advances in automation, robotics, and data analytics are optimizing HTS workflows, making them more adaptable to DEL applications. Artificial intelligence and machine learning algorithms are further enhancing analysis by improving target interaction predictions and prioritizing hits. These capabilities are essential in the discovery of novel therapeutics for oncology, infectious diseases, and neurological disorders, fueling broader market adoption. Key Market Players Merck KGaA GenScript Biotech Corporation Pharmaron Beijing Co., Ltd. WuXi AppTec Co., Ltd. Aurigene Pharmaceutical Services Limited BOC Sciences LGC Bioresearch Technologies SPT Labtech Ltd. Charles River Laboratories International, Inc. Life Chemicals Inc. Report Scope In this report, the Global DNA-encoded Library Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: DNA-encoded Library Market, By Product & Service: Kits & Reagents Encoded Libraries Design & Synthesis Services Screening Services Others DNA-encoded Library Market, By Therapeutic Area: Oncology Infectious Diseases Cardiovascular Diseases Neurological Diseases Autoimmune Diseases Metabolic Diseases Others DNA-encoded Library Market, By Application: Hit Generation / Identification Hit to Lead Hit Validation / Optimization Others DNA-encoded Library Market, By End Use: Academic & Research Institutes Pharmaceutical & Biotechnology Companies Contract Research Organizations Others DNA-encoded Library Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
